Across TCGA pan-cancer cohorts, BAIAP2L2 mass-spec protein differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of BAIAP2L2’s most consistent transcriptional readouts.
The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where BAIAP2L2 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types BAIAP2L2 is over-expressed in tumor, although a few such as CCRCC show the opposite, repressed pattern.
CCRCC and PDAC are the cancer types where BAIAP2L2 tumor–normal differential expression is most reproducible.